Miglena Marinova Achkar | Medicine | Innovative Research Award

Published on by Scientific World Research Awards

Innovative Research Award

Researcher Information
Affiliation Medical University Varna
Country Bulgaria
Scopus ID 57739433300
Documents 3
Citations 33
h-index 2
Subject Area Medicine
Event Scientific World Research Awards

Miglena Marinova Achkar

Medical University Varna, Bulgaria

Miglena Marinova Achkar is affiliated with Medical University Varna, Bulgaria, and has contributed to medical research focusing on pediatric allergy, environmental determinants of disease, and preventive healthcare. Her scholarly publications demonstrate an evidence-based approach to clinical medicine and public health, making her profile relevant for recognition through the Scientific World Research Awards.[1]

Abstract

This article summarizes the academic profile of Miglena Marinova Achkar, highlighting scholarly activities in medicine, pediatric allergy, and environmental health research. Available publication metrics and research outputs indicate contributions supporting evidence-based healthcare and preventive medicine while demonstrating suitability for academic recognition.[1]

Keywords

Medicine, Pediatrics, Allergy, Environmental Health, Atopy, Child Health, Epidemiology, Preventive Medicine, Clinical Research, Bulgaria

Introduction

Miglena Marinova Achkar’s research focuses on pediatric medicine and allergic diseases, emphasizing environmental influences on childhood health. Her published studies contribute valuable clinical observations supporting preventive healthcare strategies and encourage evidence-based decision-making for physicians, researchers, and healthcare policymakers.[1]

Research Profile

Her Scopus profile includes peer-reviewed publications addressing pediatric allergy and environmental determinants affecting children’s health. With measurable citations and an established h-index, her academic record reflects participation in internationally indexed research contributing to contemporary medical knowledge.[1]

Research Contributions

Her investigations examine relationships between environmental exposures and allergic conditions among children with hereditary susceptibility. These findings provide clinically relevant evidence supporting early prevention, risk assessment, and improved understanding of pediatric allergic disease development within healthcare practice.[1]

Publications

Published research includes studies investigating environmental determinants of allergic diseases in children, emphasizing epidemiological evaluation and clinical interpretation. These peer-reviewed publications contribute reliable scientific evidence supporting pediatric medicine, allergy prevention, and public health research initiatives.[1]

Research Impact

Citation metrics indicate that her work has attracted scholarly attention within pediatric and allergy research communities. The research supports ongoing investigations into childhood allergic diseases and contributes useful evidence for improving preventive healthcare and clinical management practices.[1]

Award Suitability

Her documented research achievements, peer-reviewed publications, citation record, and commitment to pediatric medical science demonstrate qualities aligned with the objectives of the Scientific World Research Awards. The profile reflects meaningful academic contributions deserving consideration for research recognition.[1]

Conclusion

Miglena Marinova Achkar has established an emerging academic profile through research addressing pediatric allergy and environmental health. Her publications, citations, and evidence-based investigations contribute to medical science while supporting continued scholarly development and international academic recognition.[1]

 

References

  1. Early-Life Environmental Determinants of Allergic Conditions in Children with Atopic Heredity: A Single Center Cross-Sectional Study from Bulgaria.
    https://www.mdpi.com/2076-3271/13/3/198
  2. Elsevier. (n.d.). Scopus author details: Miglena Marinova Achkar, Author ID 57739433300. Scopus.

    https://www.scopus.com/authid/detail.uri?authorId=57739433300
  3. Scientific World Research Awards. (n.d.). Scientific World Research Awards.
    https://scientificworld.net/

Sihe Zhang | Medicine | Distinguished Scientist Award

Published on by Scientific World Research Awards

Distinguished Scientist Award

Sihe Zhang
Nankai University, China

Sihe Zhang
Affiliation Nankai University
Country China
Scopus ID 7409373738
Documents 55
Citations 1,269
h-index 16
Subject Area Medicine
Event Scientific World Research Awards
ORCID 0000-0002-8923-1993

The Distinguished Scientist Award recognizes the scholarly achievements of Sihe Zhang, Professor and Director at Nankai University School of Medicine. His research focuses on cancer biology, drug delivery systems, endocytosis, extracellular vesicles, antibody therapeutics, and translational medicine. Through sustained contributions to hepatocellular carcinoma and ovarian cancer research, he has developed innovative approaches that connect molecular mechanisms with therapeutic applications.[1]

Abstract

Sihe Zhang is a biomedical researcher whose work spans cancer biology, antibody engineering, cellular uptake mechanisms, extracellular vesicle biology, and targeted therapeutic delivery. His investigations have contributed to understanding macropinocytosis, endocytic recycling, tumor progression, and resistance mechanisms in hepatocellular and ovarian cancers. He has also participated in the development of innovative antibody-based therapies and nanomedicine strategies aimed at improving treatment specificity and efficacy. His publication portfolio demonstrates a sustained commitment to translational medical research and interdisciplinary collaboration, supporting advancements in cancer diagnosis, drug delivery, and precision medicine.[1][2]

Keywords

Cancer Biology; Drug Delivery; Endocytosis; Extracellular Vesicles; Antibody Therapeutics; Hepatocellular Carcinoma; Ovarian Cancer; Nanomedicine.

Introduction

Professor Zhang has held academic positions at Nankai University and previously at the Fourth Military Medical University. His career reflects long-term engagement with molecular medicine and cell biology, emphasizing mechanisms that influence cancer progression and treatment response.[1]

Research Profile

His research profile combines laboratory discovery with translational applications. Major themes include cellular trafficking, therapeutic antibodies, tumor microenvironment studies, and targeted delivery platforms designed to improve treatment outcomes in oncology.[1]

Research Contributions

Notable contributions include investigations into CD147-mediated signaling, extracellular vesicle uptake, macropinocytosis-driven drug resistance, and antibody-based cancer therapies. These studies have expanded understanding of tumor biology and therapeutic targeting strategies.[2][3]

Publications

His scholarly record includes 55 indexed publications. Representative works address hepatocellular carcinoma resistance mechanisms, extracellular vesicle biology, peptide delivery systems, anti-CD147 therapeutics, and nanobiotechnology-based treatment approaches.[2][4]

Research Impact

With 1,269 citations and an h-index of 16, his research has influenced studies in cancer therapeutics, molecular oncology, and biomedical engineering. The impact of his work is reflected through citations, collaborations, and peer-review activities across leading journals.[1]

Award Suitability

The breadth of Professor Zhang’s contributions, combined with sustained publication output and translational relevance, aligns with the objectives of the Scientific World Research Awards. His work demonstrates scientific rigor and practical relevance in medicine.[1]

Conclusion

Sihe Zhang has established a recognized research portfolio in cancer biology and therapeutic innovation. His scholarly achievements and ongoing contributions support recognition through the Distinguished Scientist Award.[1]

References

  1. ORCID. (2026). Sihe Zhang (0000-0002-8923-1993) Research Profile.https://orcid.org/0000-0002-8923-1993
  2. Qian, L., et al. (2025). The uptake of extracellular vesicles: Research progress in cancer drug resistance and beyond. Drug Resistance Updates.https://doi.org/10.1016/j.drup.2025.101209
  3. Qi, F.Z., et al. (2024). Hypoxia-activated ADCC-enhanced humanized anti-CD147 antibody. MedComm.https://doi.org/10.1002/mco2.512
  4. Sun, Z., et al. (2023). Cell-Penetrating Peptide-Based Delivery of Macromolecular Drugs. Biomedicines.https://doi.org/10.3390/biomedicines11071971
  5. Wang, B., et al. (2024). Hypoxia-activated selectivity-improved anti-PKM2 antibody combined with prodrug TH-302. International Journal of Biological Sciences.https://doi.org/10.7150/ijbs.92211

Yoshiya Tanaka | Medicine | Innovative Research Award

Published on by Scientific World Research Awards

Innovative Research Award

Yoshiya Tanaka

Yoshiya Tanaka
Affiliation Hospital of University of Occupational and Environmental Health
Country Japan
Scopus ID 56328279400
Documents 1,326
Citations 50,831
h-index 99
Subject Area Medicine
Event Scientific World Research Awards

Yoshiya Tanaka, Hospital of University of Occupational and Environmental Health, Japan, is recognized for substantial contributions to rheumatology, immunology, and autoimmune disease research. His scholarly output, clinical investigations, and leadership in international collaborations have supported advancements in evidence-based medical practice and therapeutic development.[1]

Abstract

The Innovative Research Award recognizes researchers whose work demonstrates sustained scientific excellence and measurable impact. Yoshiya Tanaka has contributed extensively to rheumatology and clinical immunology through studies on autoimmune diseases, inflammatory mechanisms, biologic therapies, and targeted treatments. His research has informed clinical guidelines, improved disease classification systems, and supported the development of therapeutic strategies for conditions such as systemic lupus erythematosus, rheumatoid arthritis, and IgG4-related disease. With a substantial publication record and broad international collaboration, his work has influenced both academic research and patient care, reflecting the objectives of the Scientific World Research Awards.[1][2]

Keywords

Rheumatology, Clinical Immunology, Autoimmune Diseases, Rheumatoid Arthritis, Systemic Lupus Erythematosus, Biologic Therapy, Translational Medicine.

Introduction

Modern rheumatology depends on interdisciplinary research linking immunology, molecular biology, and clinical practice. Yoshiya Tanaka has participated in investigations that enhanced understanding of inflammatory pathways and treatment approaches for immune-mediated diseases.[3]

Research Profile

As Professor and Chairman in rheumatology and clinical immunology, Tanaka has developed a research portfolio focused on disease mechanisms, therapeutic innovation, and clinical trial leadership. His scholarly record reflects long-term engagement with translational medicine and global collaboration.[1]

Research Contributions

Key contributions include studies supporting lupus classification criteria, IgG4-related disease frameworks, Janus kinase inhibitor development, and biologic treatment evaluation. These efforts have contributed to improved disease assessment and therapeutic decision-making.[2][4]

Publications

  • 2019 EULAR/ACR Classification Criteria for Systemic Lupus Erythematosus.
  • Trial of Anifrolumab in Active Systemic Lupus Erythematosus.
  • Janus Kinase-Targeting Therapies in Rheumatology.

Research Impact

The researcher’s publications have received extensive citations, demonstrating influence across clinical medicine and immunology. Findings from collaborative studies have informed guidelines, therapeutic development, and evidence-based healthcare practices internationally.[1][5]

Award Suitability

The breadth of scientific output, citation performance, clinical relevance, and leadership in collaborative research aligns with the objectives of the Innovative Research Award. His contributions demonstrate sustained scholarly influence and practical significance in medicine.

Conclusion

Yoshiya Tanaka’s career reflects a consistent commitment to advancing knowledge in rheumatology and autoimmune disease research. His achievements support recognition within international scientific award programs and academic communities.

References

  1. Elsevier. (n.d.). Scopus author details: Yoshiya Tanaka, Author ID 56328279400. Scopus.
    https://www.scopus.com/authid/detail.uri?authorId=56328279400
  2. Aringer, M., et al. (2019). 2019 EULAR/ACR Classification Criteria for Systemic Lupus Erythematosus.
    DOI: https://doi.org/10.1002/art.40930
  3. Tanaka, Y., Adams, D.H., & Shaw, S. (1993). T-cell Adhesion Induced by Proteoglycan-Immobilized Cytokine MIP-1β.
    DOI: https://doi.org/10.1038/361079a0
  4. Tanaka, Y., Luo, Y., O’Shea, J.J., & Nakayamada, S. (2022). Janus Kinase-Targeting Therapies in Rheumatology.
    DOI: https://doi.org/10.1038/s41584-021-00726-8
  5. Google Scholar. (2026). Yoshiya Tanaka Citation Profile.
    https://scholar.google.com/citations?user=t_hAg7QAAAAJ&hl=en

Lina Posada Calderon | Medicine | Research Excellence Award

Published on by Scientific World Research Awards

Dr. Lina Posada Calderon | Medicine | Research Excellence Award

Resident | New York Presbyterian | United States

Dr. Lina Posada Calderon is an accomplished biomedical researcher at Weill Cornell Medicine, New York, specializing in translational and molecular cancer research. Her work focuses on the clinical and molecular characterization of cancers, precision oncology, biomarker discovery, and genetic drivers of tumor progression, with particular emphasis on KRAS-mutated malignancies. She has strong expertise in molecular biology, cancer genomics, clinical data analysis, interdisciplinary research, and high-impact scientific publishing. Her research bridges laboratory discoveries with patient-centered clinical outcomes. Dr. Posada Calderon has published 12 Scopus-indexed documents, receiving 61 citations, and holds an h-index of 5, reflecting her growing scholarly impact and emerging leadership in precision cancer research.

 

Citation Metrics (Scopus)

61
45
30
15
0

Citations

61

Documents

12

h-index

5

Citations

Documents

h-index

View Scopus Profile
 View Google Scholar

Featured Publications